Literature DB >> 19184989

A peptide antagonist of the TLR4-MD2 interaction.

Peter F Slivka1, Mitesh Shridhar, Gui-in Lee, Deanne W Sammond, Mark R Hutchinson, Alexander J Martinko, Madison M Buchanan, Page W Sholar, Jeffrey J Kearney, Jacqueline A Harrison, Linda R Watkins, Hang Yin.   

Abstract

Toll-like receptors are an integral part of innate immunity in the central nervous system (CNS); they orchestrate a robust defense in response to both exogenous and endogenous danger signals. Recently, toll-like receptor 4 (TLR4) has emerged as a therapeutic target for the treatment of CNS-related diseases such as sepsis and chronic pain. We herein report a chemical biology approach by using a rationally designed peptide inhibitor to disrupt the TLR4-MD2 association, thereby blocking TLR4 signaling.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19184989      PMCID： PMC2982775          DOI： 10.1002/cbic.200800769

Source DB:  PubMed          Journal:  Chembiochem        ISSN： 1439-4227            Impact factor:   3.164


  26 in total

1.  The danger model: a renewed sense of self.

Authors:  Polly Matzinger
Journal:  Science       Date:  2002-04-12       Impact factor: 47.728

2.  Native protein sequences are close to optimal for their structures.

Authors:  B Kuhlman; D Baker
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

Review 3.  TLR signaling pathways.

Authors:  Kiyoshi Takeda; Shizuo Akira
Journal:  Semin Immunol       Date:  2004-02       Impact factor: 11.130

4.  Protein structure prediction using Rosetta.

Authors:  Carol A Rohl; Charlie E M Strauss; Kira M S Misura; David Baker
Journal:  Methods Enzymol       Date:  2004       Impact factor: 1.600

5.  Cellular events mediated by lipopolysaccharide-stimulated toll-like receptor 4. MD-2 is required for activation of mitogen-activated protein kinases and Elk-1.

Authors:  H Yang; D W Young; F Gusovsky; J C Chow
Journal:  J Biol Chem       Date:  2000-07-07       Impact factor: 5.157

6.  Phosphatidylinositol 3-kinase is involved in Toll-like receptor 4-mediated cytokine expression in mouse macrophages.

Authors:  Marja Ojaniemi; Virpi Glumoff; Kirsi Harju; Mari Liljeroos; Kristiina Vuori; Mikko Hallman
Journal:  Eur J Immunol       Date:  2003-03       Impact factor: 5.532

7.  Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction.

Authors:  Alberto Visintin; Eicke Latz; Brian G Monks; Terje Espevik; Douglas T Golenbock
Journal:  J Biol Chem       Date:  2003-09-05       Impact factor: 5.157

8.  Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway.

Authors:  Seija Lehnardt; Leon Massillon; Pamela Follett; Frances E Jensen; Rajiv Ratan; Paul A Rosenberg; Joseph J Volpe; Timothy Vartanian
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-24       Impact factor: 11.205

Review 9.  Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia.

Authors:  Joyce A DeLeo; Flobert Y Tanga; Vivianne L Tawfik
Journal:  Neuroscientist       Date:  2004-02       Impact factor: 7.519

10.  MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4.

Authors:  R Shimazu; S Akashi; H Ogata; Y Nagai; K Fukudome; K Miyake; M Kimoto
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307
View more
  22 in total

Review 1.  Targeting protein-protein interfaces using macrocyclic peptides.

Authors:  Meng Gao; Kui Cheng; Hang Yin
Journal:  Biopolymers       Date:  2015-07       Impact factor: 2.505

Review 2.  The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia.

Authors:  Linda R Watkins; Mark R Hutchinson; Kenner C Rice; Steven F Maier
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

3.  An MD2 hot-spot-mimicking peptide that suppresses TLR4-mediated inflammatory response in vitro and in vivo.

Authors:  Liping Liu; Nilanjan Ghosh; Peter F Slivka; Zeno Fiorini; Mark R Hutchinson; Linda R Watkins; Hang Yin
Journal:  Chembiochem       Date:  2011-06-15       Impact factor: 3.164

4.  Morphine activates neuroinflammation in a manner parallel to endotoxin.

Authors:  Xiaohui Wang; Lisa C Loram; Khara Ramos; Armando J de Jesus; Jacob Thomas; Kui Cheng; Anireddy Reddy; Andrew A Somogyi; Mark R Hutchinson; Linda R Watkins; Hang Yin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-02       Impact factor: 11.205

5.  Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity.

Authors:  M R Hutchinson; L C Loram; Y Zhang; M Shridhar; N Rezvani; D Berkelhammer; S Phipps; P S Foster; K Landgraf; J J Falke; K C Rice; S F Maier; H Yin; L R Watkins
Journal:  Neuroscience       Date:  2010-04-08       Impact factor: 3.590

6.  Rationally Designed Macrocyclic Peptides as Synergistic Agonists of LPS-Induced Inflammatory Response.

Authors:  Meng Gao; Nir London; Kui Cheng; Ryo Tamura; Jialin Jin; Ora Schueler-Furman; Hang Yin
Journal:  Tetrahedron       Date:  2014-10-21       Impact factor: 2.457

Review 7.  Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation.

Authors:  Jing Li; Adam Csakai; Jialin Jin; Fengchun Zhang; Hang Yin
Journal:  ChemMedChem       Date:  2015-07-01       Impact factor: 3.466

Review 8.  Toll-like receptor 4 in CNS pathologies.

Authors:  Madison M Buchanan; Mark Hutchinson; Linda R Watkins; Hang Yin
Journal:  J Neurochem       Date:  2010-04-06       Impact factor: 5.372

Review 9.  Targeting Toll-like receptors with small molecule agents.

Authors:  Xiaohui Wang; Christina Smith; Hang Yin
Journal:  Chem Soc Rev       Date:  2013-06-21       Impact factor: 54.564

Review 10.  Contributions and Future Directions for Structural Biology in the Study of Allergens.

Authors:  Geoffrey A Mueller
Journal:  Int Arch Allergy Immunol       Date:  2017-10-10       Impact factor: 2.749
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.